Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18397749 | 1.00 | LY96 (0.38) | LY96KDM4EKMT2ATSHRHTT | |
| SCHEMBL18301080 | 0.84 | LY96 (0.40) | LY96KDM4EKMT2AHTTHPGD | |
| SCHEMBL18311967 | 0.84 | LY96 (0.40) | LY96KDM4EKMT2AHTTHPGD | |
| SCHEMBL19744095 | 0.84 | ATM (0.43) | KMT2AHTTHSD17B10NPC1MAPT | |
| SCHEMBL19744209 | 0.84 | ATM (0.43) | KMT2AHTTHSD17B10NPC1MAPT | |
| SCHEMBL28268091 | 0.83 | LY96 (0.39) | LY96KDM4EKMT2AHTTHPGD | |
| SCHEMBL28269479 | 0.82 | CYP11B1 (0.46) | LY96KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL19744001 | 0.79 | MAOB (0.42) | KDM4EKMT2ATSHRNPC1RAB9A | |
| SCHEMBL19744201 | 0.79 | MAOB (0.42) | KDM4EKMT2ATSHRNPC1RAB9A | |
| SCHEMBL14458708 | 0.79 | KDM4E (0.52) | KDM4EKMT2ATSHRHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3325462-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015221-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LY96 1068/4885KDM4E 1498/4885KMT2A 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.